CHIGENOVO Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 70

Employees

  • Latest Deal Type
  • Series B2

  • Latest Deal Amount
  • $16.6M

  • Investors
  • 12

CHIGENOVO General Information

Description

Developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases. The company specializes in developing ophthalmic gene therapy drugs backed by accurate gene diagnosis, providing reliable ophthalmic gene pharmaceuticals for the public.

Contact Information

Formerly Known As
Chinagene Tech, Chinagene Technology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Area D, Building 1, Number 27, Life Park Road
  • Zhongguancun Life Science Park, Changping District
  • Beijing, 102206
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Services
Vertical(s)
Corporate Office
  • Area D, Building 1, Number 27, Life Park Road
  • Zhongguancun Life Science Park, Changping District
  • Beijing, 102206
  • China
+86 010

CHIGENOVO Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CHIGENOVO Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B2) 20-May-2026 $16.6M Completed Generating Revenue
7. Later Stage VC (Series B1) 16-Sep-2025 Completed Generating Revenue
6. Later Stage VC (Series B) 27-Sep-2023 Completed Generating Revenue
5. Later Stage VC (Series A) 24-Mar-2022 Completed Generating Revenue
4. Later Stage VC 20-Jun-2021 Completed Generating Revenue
3. Early Stage VC (Series 2) 28-Dec-2020 Completed Generating Revenue
2. Early Stage VC 22-May-2019 $2.19M Completed Generating Revenue
1. Early Stage VC (Series 1) 01-Oct-2018 $2.19M $2.19M Completed Generating Revenue
To view CHIGENOVO’s complete valuation and funding history, request access »

CHIGENOVO Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases. The com
Drug Discovery
Beijing, China
70 As of 2026

Philadelphia, PA
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CHIGENOVO Competitors (2)

One of CHIGENOVO’s 2 competitors is Spark Therapeutics, a Formerly VC-backed company based in Philadelphia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Spark Therapeutics Formerly VC-backed Philadelphia, PA
MeiraGTx Formerly VC-backed New York, NY
You’re viewing 2 of 2 competitors. Get the full list »

CHIGENOVO Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CHIGENOVO Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
C-MER Medical Holdings Corporation Minority
Kunlun Capital Family Office Minority
Huayi Capital Venture Capital Minority
Junci Investment Growth/Expansion Minority
Lapam Capital Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

CHIGENOVO Investments (1)

CHIGENOVO’s most recent deal was a Early Stage VC with Ubrigene for . The deal was made on 18-Oct-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ubrigene 18-Oct-2019 Early Stage VC Other Pharmaceuticals and Biotechnology
To view CHIGENOVO’s complete investments history, request access »

CHIGENOVO FAQs

  • When was CHIGENOVO founded?

    CHIGENOVO was founded in 2016.

  • Where is CHIGENOVO headquartered?

    CHIGENOVO is headquartered in Beijing, China.

  • What is the size of CHIGENOVO?

    CHIGENOVO has 70 total employees.

  • What industry is CHIGENOVO in?

    CHIGENOVO’s primary industry is Drug Discovery.

  • Is CHIGENOVO a private or public company?

    CHIGENOVO is a Private company.

  • What is the current valuation of CHIGENOVO?

    The current valuation of CHIGENOVO is .

  • What is CHIGENOVO’s current revenue?

    The current revenue for CHIGENOVO is .

  • How much funding has CHIGENOVO raised over time?

    CHIGENOVO has raised $57.6M.

  • Who are CHIGENOVO’s investors?

    C-MER Medical Holdings, Kunlun Capital, Huayi Capital, Junci Investment, and Lapam Capital are 5 of 12 investors who have invested in CHIGENOVO.

  • Who are CHIGENOVO’s competitors?

    Spark Therapeutics and MeiraGTx are competitors of CHIGENOVO.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process